Aprea Therapeutics, Inc. filed a Form 8-K on November 4, 2026, reporting its financial results for the three and nine months ended September 30, 2026, and providing an operational update for the same period.

Key Highlights

  • Reporting period: Financial results cover the three and nine months ended September 30, 2026.
  • Press release attached: A press release dated November 4, 2026, announcing the results is furnished as Exhibit 99.1.
  • Corporate presentation updated: The company filed an updated corporate presentation slide deck for November 2026 as Exhibit 99.2.
  • Signed by: Oren Gilad, Ph.D., President and Chief Executive Officer, signed the filing on November 4, 2026.
  • Listing: Common stock, par value $0.001 per share, trades on NASDAQ:APRE.

Aprea Therapeutics Furnishes Q3 2026 Earnings Press Release and Updated Corporate Presentation

Aprea Therapeutics, Inc. (NASDAQ:APRE) filed a current report on November 4, 2026, disclosing financial results and an operational update under Item 2.02 of Form 8-K. According to the filing, the company issued a press release on November 4, 2026, covering results for the three and nine months ended September 30, 2026. That press release is attached as Exhibit 99.1 and was furnished, not filed, with the SEC.

The filing notes that, in accordance with General Instruction B.2 of Form 8-K, the information provided under Item 2.02, including Exhibit 99.1, "shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended." As a result, that exhibit is not subject to the liabilities of that section and is not automatically incorporated by reference into other company filings unless expressly stated.

Under Item 8.01, the company separately disclosed that it updated its corporate presentation slide deck on November 4, 2026. That presentation, labeled as Exhibit 99.2 and titled "Corporate Presentation (November 2026)," is filed, rather than furnished, and is incorporated into the report by reference. The filing was signed by Oren Gilad, Ph.D., in his capacity as President and Chief Executive Officer.

What Was Disclosed

Aprea Therapeutics filed an 8-K on November 4, 2026, furnishing a Q3 2026 earnings press release as Exhibit 99.1 and filing an updated November 2026 corporate presentation slide deck as Exhibit 99.2.